Cancer Conversations™: PARP Inhibitors in Ovarian Cancer

Download these slides from a live webinar to learn how to optimally manage ovarian cancer leveraging PARP inhibitors.
Ursula Matulonis, MD
Program Director
Robert L. Coleman, MD, FACOG, FACS
person default
Kathleen Moore, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 744 KB
Released: October 18, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Merck Sharp & Dohme Corp.

Related Content

Downloadable short slideset from CCO on recognizing and managing ocular toxicities associated with antibody–drug conjugates.

Asim V. Farooq, MD Joann Kang, MD Paul G. Richardson, MD Released: November 29, 2021

Podcast episode with expert insights on important trial data for ovarian and endometrial cancers from the ESGO 2021 annual meeting, from Clinical Care Options (CCO)

Nicole Concin, MD, PhD Released: November 23, 2021

Virtual presentation by Angeles Alvarez Secord, MD, MHSc, on individualizing care for women with cervical cancer based on current and emerging clinical data, from Clinical Care Options (CCO)

Angeles Alvarez Secord, MD, MHSc Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: November 22, 2021 Expired: November 21, 2022

Virtual presentation by Angeles Alvarez Secord, MD, MHSc, on patient underrepresented and minority women enrollment on clinical trials for cervical cancer, from Clinical Care Options (CCO)

Angeles Alvarez Secord, MD, MHSc Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: November 16, 2021 Expired: November 15, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue